The released batch was manufactured at Everest's Jiashan manufacturing site using the Company's proprietary mRNA platform, in compliance with global GMP standards. EVM14 is an off-the-shelf ...

A study in Chemistry A European Journal reveals that reduced MUC1 antigen density on gold nanoparticles still elicits potent ...

While research in mice has shown encouraging results, the next phases of human trials will need to confirm safety and ...

Quanyin Hu, a professor in the UW-Madison School of Pharmacy, said the approach could theoretically be applied to any cancer ...

We could be on the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. This paves the way for it to move ...

Using a newly discovered byproduct of dying cancer cells, University of Wisconsin–Madison researchers are developing ...

US researchers have found that developing personalised vaccines can play a key role in keeping aggressive tumours from ...

Pancreatic cancer has a five-year survival rate of just 13%, making it the deadliest cancer, according to the American Cancer ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the ...

For decades, vaccines have been seen as tools to prevent disease, protecting us from measles, flu, and even certain types of ...

GEO-CM04S1 Demonstrates Superior T Cell Responses Compared to mRNA Vaccine in Phase 2 Trial Among Immunocompromised Patients ...